MedTrace Logo

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

NCT05414500 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-09

No results posted yet for this study

Summary

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab.

The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.

Conditions

Interventions

DRUG

Mogamulizumab

Administered IV

DRUG

Brentuximab vedotin

Administered IV

Sponsors & Collaborators

  • Seagen Inc.

    collaborator INDUSTRY

  • Kyowa Kirin, Inc.

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Amit Mehta, M.D. · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2026-04-30
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414500 on ClinicalTrials.gov